Skip Nav Destination
Close Modal
1-20 of 662 Search Results for
pharmaceutical
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Journal Article
J Health Polit Policy Law (2012) 37 (5): 779–814.
Published: 01 October 2012
..., Australia, and the United Kingdom — specifically, why Canada alone failed to adopt nationwide, public pharmaceutical insurance. It demonstrates that the pace of change has significant implications for the scope of policy development. It provides new mechanisms to explain why incremental reforms stall based...
Journal Article
J Health Polit Policy Law (2013) 38 (3): 505–544.
Published: 01 June 2013
...Denis G. Arnold; James L. Oakley As the pharmaceutical industry lobbies European regulators to permit direct-to-consumer advertising (DTCA) of prescription drugs in the European Union, we found that five leading companies violated industry-developed and -promulgated standards for ethical...
Journal Article
J Health Polit Policy Law (2013) 38 (4): 735–755.
Published: 01 August 2013
...Bhaven N. Sampat; Tahir Amin The 1995 Trade Related Intellectual Property Rights (TRIPS) agreement required developing countries to grant product patents in pharmaceuticals. Developing countries have since explored various measures to ameliorate potential negative effects of the new laws on public...
Journal Article
J Health Polit Policy Law (1992) 17 (4): 847–868.
Published: 01 August 1992
...Louis H. Orzack; Kenneth I. Kaitin; Louis Lasagna The European Community (EC) plans to create a single market for pharmaceutical medicines, but the drug industry is closely linked to cultural and societal values concerning health; to the national regulatory agencies responsible for the evaluation...
Journal Article
J Health Polit Policy Law (2003) 28 (1): 109–132.
Published: 01 February 2003
...Ramón Castellblanch A comparison of the Vermont and Maine cases of attempting to control pharmaceutical prices in the year 2000 shows that the Maine legislators were more successful in challenging pharmaceutical industry political power. This comparison shows that challenging the industry...
Journal Article
J Health Polit Policy Law (2009) 34 (6): 931–977.
Published: 01 December 2009
...John Abraham Coinciding with sixty years of the U.K. National Health Service (NHS), this article reviews the neglected area of the governance of the pharmaceutical industry and the NHS. It traces the relationships between the pharmaceutical industry, the state, and the NHS from the creation...
Journal Article
J Health Polit Policy Law (2019) 44 (5): 765–787.
Published: 01 October 2019
...Denis G. Arnold; James L. Oakley Abstract Context: Spending on direct-to-consumer advertising (DTCA) for prescription pharmaceuticals has risen to record levels, five times as much as in 1996 in inflation-adjusted dollars. Major health care provider organizations have called for additional...
FIGURES
| View All (4)
Journal Article
J Health Polit Policy Law (2014) 39 (3): 691–705.
Published: 01 June 2014
... political and regulatory environment, this report explores pharmaceutical pricing options for Russia that balance greater access to medicines with achieving government plans of boosting local pharmaceutical production. To match innovative medicine prices with their health benefits, in the long run, we...
FIGURES
Journal Article
J Health Polit Policy Law (2016) 41 (2): 157–179.
Published: 01 April 2016
...Denis G. Arnold; Jennifer L. Troyer Abstract The pharmaceutical industry has been criticized for developing and aggressively marketing drugs that do not provide significant health benefits relative to existing drugs but retain the benefits of patent protection. Critics argue that drug marketing...
FIGURES
Journal Article
J Health Polit Policy Law (2006) 31 (5): 1015–1019.
Published: 01 October 2006
.... Christopher Scott Harrison. The Politics of the International Pricing of Prescription Drugs. Westport, CT: Praeger, 2004. 224 pp. $65.95 cloth. Richard Henry Parrish II. Defining Drugs: How Government Became the Arbiter of Pharmaceutical Fact. New Brunswick, NJ: Transaction Books, 2003. 163 pp. $29.95...
Journal Article
J Health Polit Policy Law (2022) 47 (5): 583–607.
Published: 01 October 2022
...Robin Feldman; Brent D. Fulton; Jamie R. Godwin; Richard M. Scheffler Abstract Context: Dramatic increases in pharmaceutical merger and acquisition (M&A) activity since 2010 suggest we are in the midst of a third wave of industry consolidation. Methods: The authors reviewed 168 economic, legal...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 629–648.
Published: 01 December 2022
...Pragya Kakani; Michael Chernew; Amitabh Chandra Abstract Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does using list prices, as is commonly done, instead of prices net of confidential rebates offered...
FIGURES
| View All (4)
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (2022) 47 (6): 835–851.
Published: 01 December 2022
... methodologies, 2013–2017. Panel A Difference in AMP estimates. Panel B Difference in Medicaid rebates. Notes : PBM = pharmaceutical benefit manager; AMP = average manufacturer price. 5i AMP slightly exceeds commercial net price because it includes Medicare Part B and other sales that are not eligible...
FIGURES
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (2022) 47 (6): 755–778.
Published: 01 December 2022
...Marc A. Rodwin Abstract This article compares the pharmaceutical pricing policies employed by public and private insurers in the United States with seven price and spending control strategies employed in the United Kingdom, France, and Germany. Differences between American and European policies...
FIGURES
Journal Article
J Health Polit Policy Law (2016) 41 (3): 423–450.
Published: 01 June 2016
...Elize Massard da Fonseca; Francisco Inácio Bastos Abstract The protection of pharmaceutical intellectual property (IP) rights is one of the most controversial debates in contemporary public health as countries have to balance incentives for drug development with the necessity of providing life...
Journal Article
J Health Polit Policy Law (2018) 43 (1): 5–18.
Published: 01 February 2018
... will require close coordination among manufacturers, payers, and regulators. Copyright © 2018 by Duke University Press 2018 Medicaid best-price rule pharmaceutical pricing value-based payment outcome-based pricing Even in today's polarized political landscape, a consensus has emerged...
Journal Article
J Health Polit Policy Law (2003) 28 (4): 615–658.
Published: 01 August 2003
...Mary E. Wiktorowicz Although industrialized nations regulate pharmaceuticals to ensure their safety and efficacy, they balance these concerns with those related to the timeliness of the approval process and the burdens involved in meeting regulatory criteria. The United States, Canada, Britain...
Journal Article
J Health Polit Policy Law (2003) 28 (2-3): 473–508.
Published: 01 June 2003
...” is usually applied to the individual or consumer level,this article develops the concept of organized voice and illustrates how it has exhibited leadership in the controversial relations between the biotech and pharmaceutical industries and society as a whole. The essay concludes by urging more research...
Journal Article
J Health Polit Policy Law (2023) 48 (2): 215–239.
Published: 01 April 2023
...Amy Kapczynski Abstract The pharmaceutical industry is among the most politically powerful business sectors in the United States today. This article describes how this industry has successfully entrenched its power, with attention to four sources of power: property power, vertical power over...
Journal Article
J Health Polit Policy Law (1998) 23 (2): 265–290.
Published: 01 April 1998
...Mae Thamer; Niall Brennan; Rafael Semansky Six countries—Canada, France, Japan, Sweden, the United Kingdom, and the United States—were studied to compare public policies affecting the development and marketing of pharmaceuticals for rare diseases (i.e., orphan drugs). Information was obtained from...
1
